Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare, inflammatory, and fibrotic diseases. The company's pipeline emphasizes its expertise in cannabinoid-based medicines, with particular interest in conditions such as cystic fibrosis, dermatomyositis, and other inflammatory disorders. Corbus aims to deliver novel treatments targeting underlying disease mechanisms to improve patient outcomes.
Company News
Corbus Pharmaceuticals announced promising Phase 1/2 clinical trial results for CRB-701, an antibody-drug conjugate targeting Nectin-4, showing robust response rates across head and neck, cervical, and urothelial cancers with a favorable safety profile.
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, ...
Corbus Pharmaceuticals (CRBP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Use these tips to buy penny stocks in December The post Buying Penny Stocks in December? 3 Top Tips to Profit appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Important events on the horizon could push these biotech stocks higher or press them further into the dirt.